glp-1 physiology informs the pharmacotherapy of obesity for Weight Loss and Diabetes Glucagon-Like Peptide-1 Receptor Agonists and

GLP-1 medications have no abuse potential and no controlled substance designation

Many patients taking GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) report altered taste experiences during treatment

What happens to the 80%+ of obesity patients not getting these drugs: Are doctors rationing access to those most likely to benefit and least likely to be harmed

Papers and patents increasingly explore combination strategies, particularly ActRII and myostatin pathway modulation, to protect muscle while deepening fat reduction [13, 14, 15]

and approved for medical use in the United States in 2006